Barclays Upgrades Phathom Pharmaceuticals to Overweight, Raises Price Target to $18

Benzinga Newsdesk www.benzinga.com Positive 92.8%

Neg 0% Neu 0% Pos 92.8%

Barclays analyst Glen Santangelo upgrades Phathom Pharmaceuticals (NASDAQ:PHAT) from Equal-Weight to Overweight and raises the price target from $16 to $18.